BiPER Therapeutics is developing first-in-class small molecules that induce unresolved endoplasmic reticulum stress to promote cancer cell death, specifically targeting gastrointestinal cancer and melanoma. The company's approach addresses the challenge of cancer cell survival and treatment resistance by focusing on key proteins involved in these processes.
Funding
$839.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, particularly gastrointestinal cancers and melanoma, develop resistance to conventional treatments by evading cell death mechanisms. These cancers often rely on specific proteins to manage endoplasmic reticulum (ER) stress, allowing them to survive and proliferate despite therapeutic interventions.
Solution
BiPER Therapeutics is developing a novel class of small molecule therapeutics designed to induce unresolved ER stress in cancer cells, leading to their death. By targeting key proteins involved in managing ER stress, BiPER's approach aims to overcome treatment resistance and selectively eliminate cancer cells. Their lead candidates, BPR001 and BPR002, are in preclinical and early clinical development, targeting gastrointestinal cancers and melanoma, respectively. The company's approach focuses on pushing cancer cells to "burn out" by disrupting their ability to cope with ER stress.
Target Audience
The primary target audience includes patients with gastrointestinal cancers and melanoma, as well as pharmaceutical companies and investors interested in novel oncology therapeutics.
Features
- First-in-class small molecules that induce unresolved endoplasmic reticulum (ER) stress.
- Selective targeting of key proteins involved in ER stress management in cancer cells.
- BPR001: Lead candidate targeting gastrointestinal cancers, currently in IND-enabling studies.
- BPR002: Candidate targeting melanoma, also in preclinical development.
- Aims to overcome treatment resistance by inducing cancer cell death through a novel mechanism.